DANIEL CHO: Open Payments
NPI 1952789471 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$667 in 28 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $107 · 2025 $667
Food & beverage: $667
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $260 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $136 |
| E.R. Squibb & Sons, L.L.C. | 4 | $106 |
| ABBVIE INC. | 3 | $70 |
| Janssen Pharmaceuticals, Inc | 2 | $60 |
| Neurocrine BioSciences, Inc. | 1 | $34 |
Products named: AUSTEDO XR, CAPLYTA, COBENFY, UZEDY, VRAYLAR, INVEGA SUSTENNA, INGREZZA.
Industry payments across HI — which companies pay providers there.
